Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety

References

• Daneshmand S, Bazargani ST, Bivalacqua TJ, et al. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry. Urol Oncol. 2018;36(8):361.e1–361.e6.
   Web of Science ®Google Scholar
• Blick CG, Nazir SA, Mallett S, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 2012;110(1):84–94.
   PubMed Web of Science ®Google Scholar
• van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review . Eur Urol. 2011;60(3):493–500.
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of Non-Muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non–muscle-invasive bladder cancer (ta, T1, and carcinoma in situ). European Urology. 2021;76(5):639–657.
   Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):465–466.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–430.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992–1001.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin . Eur Urol. 2016;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Rodríguez O, Hernández V, et al. European association of urology (EAU) prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. European Urology. 2021;79(4):480–488.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657.
   Web of Science ®Google Scholar
• Soukup V, Babjuk M, Bellmunt J, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012;62(2):290–302.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–189.
   PubMed Web of Science ®Google Scholar
• Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc. 2018;106(4):531–541.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Murad MH, Mustafa RA, Schünemann HJ, et al. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85–87.
   PubMedGoogle Scholar
• Hernández V, Llorente C, de la Peña E, et al. Long-term oncological outcomes of an active surveillance program in recurrent low grade ta bladder cancer. Urol Oncol. 2016;34(4):165.e19–165.e23.
   Web of Science ®Google Scholar
• Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995;172:33–36.
   PubMedGoogle Scholar
• van der Aa MN, Steyerberg EW, Bangma C, et al. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol. 2010;183(1):76–80.
   PubMed Web of Science ®Google Scholar
• van der Aa MN, Steyerberg EW, Sen EF, et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int. 2008; 101(9):1106–1110.
   PubMed Web of Science ®Google Scholar
• Van Der Poel HG. Editorial comment on: microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (cost-effectiveness of follow-up of urinary bladder cancer trial CEFUB). Eur Urol. 2009;55(3):667–668.
   PubMed Web of Science ®Google Scholar
• Niwa N, Matsumoto K, Hayakawa N, et al. Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: a matched-pair analysis. Urol Oncol. 2015;33(9):386.e15–e21.
   Web of Science ®Google Scholar
• Hurle R, Casale P, Saita A, et al. Clinical performance of expert bladder cancer (BC) monitor, a mRNA-based urine test, in active surveillance (as) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the bladder cancer Italian active surveillance (BIAS) project. World J Urol. 2020;38(9):2215–2220.
   PubMed Web of Science ®Google Scholar
• Kavalieris L, O'Sullivan P, Frampton C, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol. 2017;197(6):1419–1426.
   PubMed Web of Science ®Google Scholar
• Valenberg F, Hiar AM, Wallace E, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol. 2019; 75(5):853–860.
   PubMed Web of Science ®Google Scholar
• Cancel-Tassin G, Roupret M, Pinar U, et al. Assessment of xpert bladder cancer monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J Urol. 2021;39(9):3329–3335.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]: Bethesda (MD): National Library of Medicine (US); [cited cited 2021 May 15]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04100733.
   Google Scholar
• Benderska-Söder N, Hovanec J, Pesch B, et al. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial*. Urol Oncol. 2020;38(12):886–895.
   PubMed Web of Science ®Google Scholar
• Tan WS, Teo CH, Chan D, et al. Mixed-methods approach to exploring patients' perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU Int. 2019;124(3):408–417.
   PubMed Web of Science ®Google Scholar
• Witjes JA. Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn in the last 24 months: a critical review. Curr Opin Urol. 2020; 30(3):387–391.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Giannatempo P, Maccagnano C, et al. Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat Res Commun. 2021; 27:100369.
   PubMedGoogle Scholar
• Mossanen M, Wang Y, Szymaniak J, et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019;37(10):2059–2065.
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho KS, Kang DH, et al. A network Meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015;15(1):566.
   PubMed Web of Science ®Google Scholar
• Rink M, Babjuk M, Catto JW, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–638.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, De Carlo F, Pagliarulo V, et al. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol. 2015;7(6):339–350.
   PubMed Web of Science ®Google Scholar
• Pinar U, Pradere B, Roupret M. Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine. Curr Opin Urol. 2021;31(4):404–408.
   PubMed Web of Science ®Google Scholar
• Shkolyar E, Jia X, Chang TC, et al. Augmented bladder tumor detection using deep learning [article]. Eur Urol. 2019;76(6):714–718.
   PubMed Web of Science ®Google Scholar